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Background: Many polyphenols have been proposed as broad-spectrum inhibitors of amyloid formation.
To investigate structure–activity relationships relevant for the interaction of ﬂavonoids with transthyr-
etin (TTR), the protein associated with familial amyloid polyneuropathy (FAP), we compared the effects of
major tea catechins and their larger polymers theaﬂavins, side-by-side, on TTR amyloid formation pro-
cess.
Methods: Interaction of ﬂavonoids with TTR and effect on TTR stability were assessed through binding
assays and isoelectric focusing in polyacrylamide gel. TTR aggregation was studied, in vitro, by dynamic
light scattering (DLS), transmission electron microscopy (TEM) and in cell culture, through cytotoxicity
assays.
Results: Tested ﬂavonoids bound to TTR and stabilized the TTR tetramer, with different potencies. The
ﬂavonoids also inhibited in vitro formation of TTR small oligomeric species and in cell culture inhibited
pathways involving caspase-3 activation and ER stress that are induced by TTR oligomers. In all assays
performed the galloyl esters presented higher potency to inhibit aggregation than the non-gallated
ﬂavonoids tested.
Conclusions: Our results highlight the presence of gallate ester moiety as key structural feature of ﬂa-
vonoids in chemical chaperoning of TTR aggregation. Upon binding to the native tetramer, gallated ﬂa-
vonoids redirect the TTR amyloidogenic pathway into unstructured nontoxic aggregation assemblies
more efﬁciently than their non-gallated forms.
General signiﬁcance: Our ﬁndings suggest that galloyl moieties greatly enhance ﬂavonoid anti-amyloid
chaperone activity and this should be taken into consideration in therapeutic candidate drug discovery.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Transthyretin (TTR) is a tetramer composed by identical sub-
units of 127-amino acids and contains an extensive β-sheet
structure [1]. TTR is predominantly synthesized in the liver and
the choroid plexus of the brain. It circulates in plasma and cere-
brospinal ﬂuid where it transports thyroid hormones (namely,
thyroxin-T4) and vitamin A (through a complex with retinol
binding protein— RBP) [2]. More than one hundred TTR single
point mutations have been reported (amyloidosismutations.com).
Most TTR variants are pathogenic and associated with extracellularB.V. This is an open access article u
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da).protein misfolding and aggregation that triggers inﬂammation,
oxidative stress, matrix remodeling, unfolded-protein-response
and endoplasmic reticulum (ER) pathways particularly along the
gastrointestinal tract and peripheral nervous system [3,4]. Among
TTR point mutations promoting amyloidogenesis, the most com-
mon is TTR V30M which deposits diffusely in the peripheral ner-
vous system, involving nerve trunks, plexuses, and sensory and
autonomic ganglia leading to Familial Amyloidotic Polyneuropathy
(FAP) [5,6]. FAP has a wide geographic distribution with the largest
foci in Portugal, Japan, and Sweden, and is estimated to affect
5000–10,000 patients worldwide [7].
Since the TTR molecule has high degree of β-sheet structure,
wild-type (WT) TTR protein is intrinsically prone to dissociate into
non-native monomers that further aggregate into β-pleated sheet
ﬁbrils [1]. Deposition of TTR WT primarily in the heart and, oc-
casionally, in carpal ligaments appears to cause senile systemic
amyloidosis [SSA], nonhereditary, age-related form of TTR amy-
loidosis that affects the elderly [8]. As most circulating mutant TTRnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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used to treat FAP since 1990s. Nevertheless, alternative and less
invasive therapeutic approaches are mandatory.
Considering the original amyloid cascade hypothesis [9], initial
efforts to develop more effective therapies for the treatment of
amyloid-related diseases focused on inhibition and/or disruption of
ﬁbrils. With the recognition that intermediate oligomeric species,
rather than mature ﬁbrils, likely were the key culprits [10], the focus
of research in the ﬁeld shifted towards the development of small-
molecule modulators that redirect the amyloidogenic cascade into
unstructured “off-pathway” nontoxic intermediates [11].
Based on compound library screening or epidemiologic studies
several closely related plant polyphenols, including catechins, thea-
ﬂavins and tannins, have been proposed as broad inhibitors of protein
aggregation and toxicity [11–14]. The physicochemical features asso-
ciated with the ability of ﬂavonoids to inhibit amyloid ﬁbril formation
are most likely the presence of aromatic rings and the ability to form
non-covalent interactions with different amino acids residues of the
protein amyloidogenic core [15]. In fact, most ﬂavonoids proved ef-
fective against amyloid beta (Aβ) abnormal misfolding have more than
two aromatic rings essential for π–π stacking interactions with hy-
drophobic amino acid residues (Tyr, Phe) of Aβ and at least threeFig. 1. Chemical structuhydroxyl groups that form hydrogen bonds with hydrophilic amino
acid residues (His6, Ser8, Tyr10, His14, Lys16) of Aβ [15]. In addition,
the planarity of the molecule is critical to increase surface contact with
amyloid peptides [16,17].
In the present study, we aimed to compare the effect of
structurally related ﬂavonoids, side-by-side, and advance our un-
derstanding on the mechanism of action of these phytochemicals
on the TTR amyloid ﬁbril formation process.2. Materials and methods
2.1. Reagents
Gallic acid, catechin, catechin gallate, epicatechin, epicatechin
gallate, epigallocatechin gallate (EGCG), theaﬂavin, theaﬂavin
monogallate, theaﬂavin digallate and tannic acid were purchased
from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Recombinant transthyretin
Recombinant wild-type TTR (TTR WT) and TTR variants, namelyres of polyphenols.
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pression system and puriﬁed as previously described [17].
2.3. Plasma samples
Whole blood from ﬁve heterozygote carriers of TTR V30M and
from ﬁve control individuals was collected in the presence of EDTA
and centrifuged for plasma separation. All donors gave informed
consent.
2.4. Thyroxine competition assays
Displacement of T4 from TTR was assayed qualitatively by in-
cubation of recombinant TTR WT (10 μg) or whole plasma (5 μL)
with [125I]T4 [speciﬁc radioactivity 1250 Ciμ /μg; Perkin-Elmer, MA,
USA] in the presence of different ﬂavonoids (10 molar excess
relative to TTR tetramer) solubilized in DMSO. Subsequently, pro-
teins were separated by PAGE [18], revealed by phosphor imaging
and quantiﬁed using the ImageQuant program version 5.1.
Competition of ﬂavonoids with T4 for the binding to TTR was
quantitatively assayed by gel ﬁltration as previously described [18].
Brieﬂy, a solution of 30 nM TTR in 0.1 M Tris, 0.1 M NaCl and 0.001M
EDTA buffer, pH 8.0 was incubated with a trace amount of [125I]T4
(50,000 cpm) plus increasing concentrations of inhibitor (0–10 μM)
overnight at 4 °C. [125I]T4 bound to TTR was separated from free T4 in a
gel ﬁltration column. All samples were run in duplicate.Fig. 2. (A) Ponceau S staining of proteins treated or non-treated [vehicle] with polyphen
glycinate staining of the membranes in (A).2.5. Nitroblue tetrazolium [NBT] staining assay
The binding of different ﬂavonoids to TTR was assayed by ni-
troblue tetrazolium (NBT) staining which detects quinone-mod-
iﬁed proteins [19]. Recombinant TTRWT and TTR V30M (2 mg/mL)
in PBS were incubated in the presence of 10 molar excess of
each ﬂavonoid for 2 h at 37 °C, or saline (as control). Then, samples
were boiled with SDS loading buffer and proteins were separated
by SDS-PAGE (15% polyacrylamide gel). The gels were electro-
blotted onto nitrocellulose membrane (GE Healthcare) and stained
with Ponceau S [0.1% in 5% acetic acid] to conﬁrm blotting. Sub-
sequently the membranes were washed with water and stained
with glycinate/NBT solution (0.24 mM NBT in 2 M potassium gly-
cinate, pH 10) for 20 min.2.6. Isoelectric focusing [IEF] in semi-dissociating conditions
Brieﬂy, 30 μL of human plasma were incubated with 5 μL of
10 mM solution of each ﬂavonoid for 1 h at 37 °C and subjected to
native PAGE. The TTR gel band was excised and applied to a semi-
dissociating (4 M urea) IEF gel containing 5% (v/v) ampholytes pH
4–6.5 (GE Healthcare) run at 1200 V for 6 h [20]. Proteins were
stained with Coomassie Blue, the gels were scanned (GS-800 Ca-
librated Densitometer; Biorad) and subjected to densitometry
using the Quantity One 1-D Analysis Software version 4.6.ols after electroblotting of SDS-PAGE gels onto nitrocellulose membranes. (B) NBT/
Fig. 3. (A) IEF analysis of plasma TTR stability after treatment with polyphenols. Plasmas from TTR V30M heterozygotic carriers were treated with polyphenols. Different
molecular species visualized in the IEF gel after Coomassie Blue staining are indicated. These gels are representative of others run in parallel. (B) The histogram shows TTR
tetramer/total TTR bands ratio obtained after densitometry of IEF gels corresponding to the analysis of 5 plasma samples from TTR V30M carriers]. *po0.05; ** po0.01; ***
po0.005.
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microscopy (TEM)
A solution of TTR Y78F (2 mg/ml) in PBS with or without 10
molar excess of different ﬂavonoids was ﬁltered through 0.2 μm
Anotop syringe ﬁlters (Whatman, England) and incubated at 37 °C
for 4, 6 and 12 days. DLS measurements were performed at 25 °C
in a Malvern Zetasizer Nano ZS (Malvern, Worcestershire, UK).
Each sample was measured tree times; average distributions are
presented. Aliquots from the samples studied by DLS were also
analyzed by TEM as previously reported [21]. Sample aliquots
(5 μL) were adsorbed to carbon-coated collodion ﬁlm supported
on 200-mesh copper grids. The grids were negatively stained with
1% uranyl acetate and visualized with a Zeiss microscope at 60 kV.
2.8. Cell culture and DoT-blot ﬁlter assay for aggregate detection
To evaluate the different ﬂavonoids as TTR aggregation in-
hibitors we used a rat Schwannoma (RN22) (American Type Cell
Collection) cell line stably transfected with TTR L55P cDNA [22].Cells were grown till 80% cell conﬂuence with the compounds at
1 μM concentration in cell medium (5 days). Then, cells were
incubated for further 24 h still in the presence of compounds but
in serum free media. TTR in the medium was quantiﬁed by ELISA,
and equal amounts of TTR (500 ng) were doted onto a 0.2 μm pore
cellulose acetate membrane—dot-blot ﬁlter assay. TTR aggregates
retained in the membrane were immunodetected using rabbit
anti-human TTR (Dako, Glostrup Denmark) (1:500) followed by
anti-rabbit HRP antibody (1:1500) and ECL
s
visualization (GE
Healthcare, Buckinghamshire, UK). Quantiﬁcation of dot-blots was
performed with a Bio-Rad ChemiDoc XRS system using the IM-
AGELAB software. Experiments were repeated at least three times
in triplicate.
2.9. Cell toxicity assays
Rat Schwannoma cells [RN22] were propagated and maintained
as described previously [21]. Brieﬂy, 80% conﬂuent cells in Dul-
becco's minimal essential mediumwith 1% fetal bovine serumwere
exposed for 16 h to 2 μM of TTR Y78F oligomers. These oligomers
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sence or presence of a 10x molar excess of different ﬂavonoids at
37 °C, for 6 days. Then, cells were trypsinized and lysed using lysis
buffer containing 5 mM EDTA, 2 mM EGTA, 20 mMMOPS, 1% Triton
X-100, 1 mM PMSF and Protease Inhibitor Mix (GE Healthcare).
After centrifugation (14,000 rpm for 20 min at 4 °C), the super-
natant was collected and used for determination of caspase-3 ac-
tivity in cell lysates and BiP detection by Western blot analysis.
Caspase-3 activation was determined using the CaspACE ﬂuori-
metric 96-well plate assay system (Sigma-Aldrich) according to
manufacturer's instructions. Protein concentration in lysates was
determined with the Bio-Rad protein assay reagent (Sigma-Aldrich).
Western blot was used to evaluate BiP protein levels in cell ly-
sates. Fifty micrograms of total protein from each tissue were se-
parated on 15% SDS-PAGE and transferred onto a nitrocellulose
Hybond-C membrane using a Mini Trans-Blot Cell (Bio-Rad) system.
The primary antibodies and the respective dilutions used were:
rabbit polyclonal anti-BiP (1:1000) (Abcam, Cambridge, UK) and
mouse polyclonal GAPDH (1:1000) (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Detection was performed with ECL
s
(GE Healthcare,
Buckinghamshire, UK). Quantiﬁcation of blots was performed with
a Bio-Rad ChemiDoc XRS system using the IMAGELAB software, and
immunosignals were normalized with GAPDH expression.
2.10. Statistical analysis
Data are expressed as the mean7SEM. One-way ANOVA fol-
lowed by Bonferroni's post-hoc comparisons tests were performed
in all statistical analyzes here presented using GraphPad Prism 5.0.
Statistics with a value of po0.05 were considered signiﬁcant.3. Results
3.1. Binding of ﬂavonoids
The structural similarities of polyphenols (Fig. 1) with thyrox-
ine, the natural TTR ligand, lead us to investigate their ability toFig. 4. TEM analysis of TTR aggregation. TTR Y78F was incubated at 37 °C under stagnan
referring to t¼0 days for Vehicle and to t¼4 days for gallic acid, arrowheads indicate s
vehicle, arrows indicate very large aggregates and arrowheads to small ﬁbrils. Scale barcompete with T4 for the binding to TTR. The compounds were
incubated with isolated TTR WT and with trace amounts of radi-
olabeled thyroxine ([125I]T4). After incubation, samples were ana-
lyzed by PAGE. Similar ex vivo assays were performed with TTR in
whole plasma from control individuals and heterozygote carriers
of TTR V30M. No signiﬁcant alteration of the TTR band intensity
was found when comparing the sample in the presence and ab-
sence of the different compounds, which indicates that none of the
compounds compete with T4 for the binding to plasma TTR, nei-
ther isolated recombinant TTR nor TTR in whole plasma from
control individuals (not shown). Competition of ﬂavonoids with
[125I]T4 for the binding to recombinant TTR WT was also tested by
a quantitative assay [18]. The results obtained demonstrate that
none of the tested compounds signiﬁcantly competed with T4 for
the binding to TTR indicating that they do not interfere with the
transport of T4 by TTR (data not shown). These results were con-
sistent with the ex vivo data from the PAGE binding assay.
However, it has been reported that green tea polyphenols react
with proteins forming complexes that are speciﬁcally detected
with NBT/glycinate redox-cycling staining [23]. Therefore, to in-
vestigate ﬂavonoids interaction with TTR WT and TTR V30M var-
iant, each protein was incubated in the presence or absence (ve-
hicle) of each polyphenol and subjected to SDS-PAGE followed by
electroblotting. A bovine serum albumin (BSA) sample incubated
with EGCG was included as positive control for protein–quinone
complex formation. The membranes were stained with Ponceau S,
to conﬁrm blotting efﬁciency, followed by NBT/glycinate staining.
Recombinant TTR WT (Fig. 2) incubated with different ﬂavonoids
showed purple protein bands of different intensity after NBT
staining, while no color reaction occurred in vehicle treated
samples. Similar results were obtained with TTR V30M (results not
shown). Interestingly, TTR incubated with gallated ﬂavonoids
showed more intense protein bands as compared to samples
treated with the non-gallated forms (ex. catechin gallate vs ca-
techin, etc). Moreover, while samples treated with non-gallated
ﬂavonoids display a major purple protein band corresponding to
the TTR monomer, in the presence of most gallated ﬂavonoids an
additional protein band consistent with the TTR dimer is observed.t conditions for 4 days in the absence (vehicle) or presence of gallic acid. In panels
oluble protein and arrows very small oligomers; in panel referring to t¼4 days for
¼500 nm.
Fig. 5. DLS analysis of TTR aggregation. TTR Y78F was incubated at 37 °C under stagnant conditions for 4 days in the absence (vehicle) or presence of polyphenols.
Representative graphs of each condition.
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phenols bind to TTR and increase protein resistance to dissociation
under the highly denaturing conditions of SDS-PAGE.The effect of ﬂavonoids on TTR tetramer stability was tested
ex vivo by IEF under semi-dissociating conditions. EGCG, pre-
viously characterized as a TTR tetramer stabilizer, was used as
Table 1
Particle intensity7SD (% )
Soluble TTR
(8 nm Dh)
TTR aggregates
(4100 nm Dh)
t¼0 days
Vehicle 91.471.7 8.671.7
t¼4 days
Vehicle 54.974.8 38.673.0
Gallic acid 84.279.4 15.879.4
Catechin 84.974.8 15.174.8
Catechin gallate 87.273.0 12.873.0
Epicatechin 79.176.8 18.974.9
Epicatechin gallate 89.270.5 10.870.5
EGCG 96.376.4 3.776.4
Theaﬂavin 67.374.0 26.373.3
Theaﬂavin
monogallate
78.975.9 19.174.9
Theaﬂavin digallate 98.370.4 1.770.4
Tannic acid 84.672.4 15.073.2
Fig. 6. Activation of caspase-3 in RN22 cells exposed to 2 μM TTR Y78F oligomers or
TTR Y78F oligomers pretreated with. *** po0.005.
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TTR presented a characteristic pattern of bands composed by
monomer, oxidized monomer and several lower pI bands corre-
sponding to different forms of tetramers (Fig. 3). The ratio tetra-
mer/total TTR (tetramerþmonomers) is typically higher
(0.5870.06) for plasma from normal individuals than for the
heterozygote TTR V30M carriers plasma (0.4070.06) (Fig. 3) [18].
The results showed that all tested ﬂavonoids signiﬁcantly sta-
bilized TTR tetramers, both from WT and V30M variant, although
with different stabilizing potencies. Overall, EGCG, gallic acid and
tannic acid displayed the highest tetramers/total protein ratios,
indicating that these compounds are the most potent TTR stabi-
lizers under the tested conditions. Interestingly, all gallated ﬂa-
vonoids slightly altered the migration of TTR tetramers in the IEF
gel.
3.2. Effect of polyphenols on TTR aggregation in vitro
Next, ﬂavonoids were tested for their effect on TTR aggregation
using the TTR Y78F recombinant protein. This mutant aggregates
under physiologic conditions, without agitation or acidiﬁcation of
the protein and its aggregation pathway has been characterized by
TEM [12]. As shown in Fig. 4, after incubation for 4 days, TTR Y78Fforms large protein aggregates and small ﬁbrils. In this study, so-
luble TTR Y78F was incubated in the absence (vehicle) or presence
of selected ﬂavonoids and tested at different time points, up to 12
days. The samples were analyzed by DLS for measurement of the
protein particles size distribution in solution. At the beginning of
the experiment, the protein sample was composed mainly by
particles of approximately 8 nm hydrodynamic diameter (dH)
[Fig. 5], which is in accordance with previous reports for the TTR
native tetrameric state [24], that evolved, after 4 days incubation,
to small oligomeric species (105 nm dH) and later to large ag-
gregates and ﬁbrils (41000 nm dH), as shown in Fig. 5. As ex-
pected from previous studies [21], EGCG incubated samples dis-
played a major particle population corresponding to native-state
TTR indicating that EGCG stabilizes TTR tetramer, thus inhibiting
protein aggregation. This inhibitory effect was observed during the
entire incubation period. Although to different extent, all tested
ﬂavonoids inhibited the formation of small oligomeric species
(50–200 nm dH) and mature ﬁbrils (41000 nm dH). Remarkably,
EGCG (96.376.4%) and theaﬂavin digallate (98.370.4) sustained
most TTR in its native conformation (8 nm dH) during prolonged
incubation (4 days) (Fig. 5; Table 1), supporting the notion that
they inhibit the TTR amyloid cascade from the initial step in the
pathway of self-assembly that is the irreversible dissociation of
tetrameric TTR to unfolded monomers. In parallel, the same
samples were analyzed by TEM for ultrastructure analysis of the
protein species in solution. As expected from previous studies [12],
TTR Y78F preparations treated with EGCG showed almost com-
plete inhibition of TTR aggregation [data not shown]. Only soluble
protein and small spherical aggregates, but no large oligomers or
ﬁbrils, could be observed for all time points analyzed [not shown].
A similar inhibitory effect was also observed in other ﬂavonoid
treated samples, particularly with samples treated with gallic acid
or gallated forms of tea catechin and theaﬂavins (data not shown).
These results were in accordance with those obtained from DLS.
3.3. Cell toxicity assays
Having characterized the inhibitory properties of the different
ﬂavonoids on TTR aggregation in vitro, the study continued with
evaluation of the cytotoxicity of the TTR molecular species generated
in the presence of phytochemicals. TTR Y78F was incubated in con-
ditions to form oligomers in presence or absence of ﬂavonoids. The
resulting preparation was added to rat Schwannoma cells and in-
cubated for 16 hours. Following, cells were lysed and Caspase-3 and
BiP activation were evaluated. The results obtained are presented in
Fig. 6. TTR oligomers added to cells considerably increased in-
tracellular Caspase-3 activity as compared to addition of soluble TTR,
as expected [25]. All tested ﬂavonoids signiﬁcantly impaired oligo-
mer formation and thus toxicity of TTR Y78F preparation, although
with different inhibitory efﬁciencies; gallic acid and galloyl esters
from catechins or theaﬂavin presented stronger inhibitory effect on
Caspase-3 activity as comparing to their ungallated forms. Under the
tested conditions, EGCG was the most potent inhibitor of caspase-
dependent pathways in TTR oligomers-induced apoptosis.
The same cell lysates were also tested for ER stress response
triggered by TTR oligomers. As expected from previous studies [4],
TTR oligomers induced an increase in the levels of ER-chaperone
BiP comparing to soluble TTR, as depicted in Fig. 7. In contrast, pre-
incubation of TTR with different ﬂavonoids exerted a protective
effect against ER-stress induction [Fig. 7]. These results are in ac-
cordance with those obtained for Caspase-3 determination.
3.4. Effect of ﬂavonoids on TTR aggregation in cell culture
In view of the in vitro results described above we examined the
impact of ﬂavonoids on TTR abnormal misfolding and toxicity in a
Fig. 7. (A) Anti-BiP Western blot of protein extracts from RN22 cells incubated with 2 μM TTR Y78F oligomers or TTR Y78F oligomers pretreated with polyphenols.
(B) Histogram: normalized Bip/GAPDH density quantiﬁcation. *po0.05; **po0.01; ***po0.005.
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aggregation was investigated in a rat Schwannoma cell line
transfected with TTR L55P that secretes the TTR variant to the
medium, where it forms small aggregates [22]. Conditioned
medium was ﬁltered through cellulose acetate membrane and the
retained TTR aggregates were immunodetected with anti-TTR
antibody. In this assay, we compared the conditioned media of
cells incubated with ﬂavonoids to the media of vehicle-treated
cells. As expected, EGCG abolished TTR aggregation in conditioned
medium (98.36%70.90 aggregation inhibition), as evident in Fig. 8
by absence of signal in the corresponding dot-blot. This effect was
surprisingly comparable to that obtained with gallic acid (99.10%
70.63). In addition, all the galloyl esters presented very similar
and high levels of inhibition of aggregation as in the case of ca-
techin gallate (95.13%71.72), epicatechin gallate (93.27%72.65),
theaﬂavin monogallate (94.19%73.28), theaﬂavin digallate
[94.70%73.60] and tannic acid (92.45%74.98). Non-gallated ﬂa-
vonoids, including catechin, epicatechin and theaﬂavin also in-
hibited TTR aggregation although with lower inhibition potency
(70%).4. Discussion
The current state of knowledge deﬁnes the amyloid cascade as a
complex, multi-step process, where protein misfolding due to mu-
tations, thermodynamics, aging or other stress factors result in ab-
normal protein self-assembly into higher-order structures. In TTR
amyloidosis, deposition and accumulation of β-sheet-rich aggregated
material in the extracellular compartment sets off a series of mole-
cular events that result in cell death. Since TTR tetramer dissociation
into partially unfolded monomers is the rate-limiting step in TTRamyloidogenic process, targeted therapies have mainly focused on
small molecules that stabilize the tetramer, inhibiting TTR amyloid
ﬁbril formation. That is the case of ongoing therapeutic strategies for
ameliorating TTR amyloidoses that include the use of small molecule
TTR stabilizers such as tafamidis meglumine (Vyndaquel
s
) and di-
ﬂunisal. In both cases Phase II/III clinical trials were recently com-
pleted for the treatment of FAP and demonstrated a slowing of dis-
ease progression in patients heterozygous for the V30M TTR muta-
tion [26]. Recent studies have highlighted alternative approaches for
intervention in amyloid formation and toxicity. In particular, plant-
derived polyphenols, including catechins [11,12,14], theaﬂavins [13],
tannins [27] and isoﬂavones [28] have been demonstrated to inhibit
the formation of aggregate intermediates of different amyloid pro-
teins in vitro and their associated cytotoxicity.
Among all polyphenols shown to interfere with amyloid pro-
tein misfolding and abnormal aggregation, tea ﬂavonoid epi-
gallocatechin gallate (EGCG) has received by far the most atten-
tion. EGCG inhibits aggregation and toxicity of various structurally
and functionally distinct amyloid proteins, including α-synuclein
[11,14], Aβ [11], prion protein PrP [29] and TTR [12,21]. While most
currently available studies suggest that EGCG preferentially inter-
acts with highly unstructured regions of intrinsically disordered
molecules, work from our group has shown that EGCG can directly
bind and stabilize TTR native tetrameric fold in vitro and in whole
plasma without disturbing TTR physiological functions, in parti-
cular the transport of T4 [12,21]. Although many efforts have been
made to elucidate the molecular mechanism of natural occurring
ﬂavonoids against amyloidogenesis, the structure–activity re-
lationship is still elusive and remains further explored.
Herein, we report the ﬁrst biochemical study of major tea catechins
and their larger polymers theaﬂavins to establish structure–activity
relationships relevant for interaction with TTR and inhibition of TTR
Fig. 8. (A) Immunodetection of TTR aggregates after dot-blot ﬁlter assay of the medium from TTR L55P transfected RN22 cells grown in the absence [vehicle] or in the
presence of polyphenols. (B) Representation of the percentage of aggregation inhibition based on quantiﬁcation of the dots obtained in (A).
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ﬂavonoids to NBT/quinone-modiﬁed TTR and found that although
they all form SDS-PAGE stable TTR-ﬂavonoid complexes, a signiﬁcant
stronger signal was observed for samples incubated with catechins
containing the galloyl moiety (gallic acid, catechin gallate, epicatechin
gallate and EGCG) or theaﬂavins as compared to the ungallated ca-
techins. In support of these observations, Ishii and colleagues [23]
reported that EGCG presented higher afﬁnity than the ungallated form
(epigallocatechin) for the binding to human serum albumin, indicating
that the galloyl moiety participated in the interaction of EGCG with
albumin.
Previously, we have demonstrated that EGCG increases plasma
TTR stability [12] and in this study we found that binding of EGCG
structurally related ﬂavonols to TTR could also impact on protein
stability and that although all tested compounds signiﬁcantly in-
creased tetramer/total ratio, gallated monomeric (catechins) or
polymeric (theaﬂavins) ﬂavon-3-ols were the most potent tetra-
mer stabilizers. Interestingly, gallated ﬂavonols presented a sig-
niﬁcant alteration on the isoelectric focusing migration (isoelectric
point) of TTR tetramers comparing to the ungallated forms. In
addition, none of the tested ﬂavonoids interferes with the trans-
port of thyroxine by TTR. Thus, our data indicate that these ﬂa-
vonoids, particularly the gallated forms, strongly interact with TTR
most likely at a region located at the surface of the molecule,
probably at the interface of both TTR dimers, similarly to what has
been described for EGCG [30].In view of the in vitro results described above we examined the
impact of ﬂavonoids on TTR abnormal misfolding and toxicity in a
cell culture system. Comparison of the effects of different ﬂavo-
noids on inhibition of TTR aggregation and toxicity appears to
correlate closely with i) the presence of gallate ester moiety in the
catechin structure and ii) the number of hydroxyl groups in the
B-ring catechin structure. Thus, the overall anti-amyloidogenic
activity of ﬂavonoids was: EGCG4gallic acid4catechin galla-
te¼epicatechin gallate¼theaﬂavin monogallate¼theaﬂavin di-
gallate¼tannic acid4theaﬂavin¼catechin¼epicatechin.
Taken together, these results highlight the importance of the
galloyl moiety on TTR anti-amyloidogenic activity associated with
tea ﬂavonoids. In support of this hypothesis, we observed a strik-
ing inhibition of TTR amyloidogenicity by gallic acid. This key
ﬁnding is in agreement with previously reported data regarding
the protective effects of ﬂavonoid galloyl esters (i.e gallic acid,
epicatechin gallate, EGCG) against β-amyloid induced toxicity
using primary cultures of rat hippocampal cells as model [31].
Furthermore, the galloyl moiety seems to be required for major
biological and pharmacological activities of tea ﬂavonols, namely
free radical-scavenging abilities [32] and antiproliferative activity
of cancer cells [33,34]. Stochastic conformational analysis in silico
performed by Kuzuhara and colleagues revealed many conforma-
tions of EGCG and epicatechin gallate indicating that the mobility
and ﬂexibility of the galloyl moiety allow these compounds to take
on multiple conformations that may be relevant for interaction
N. Ferreira et al. / Biochemistry and Biophysics Reports 3 (2015) 123–133132with different molecular targets [35]. In addition, the presence of
3-trihydroxyl groups attached to the B-ring in EGCG enhances its
anti-aggregation efﬁciency in comparison to those with dihydroxyl
groups (catechin gallate and epicatechin gallate). Thus, the num-
ber of hydroxyl groups on the B-ring and D-Ring seems to impact
on the anti-amyloidogenic potency of catechin gallate esters.
Although we present here the ﬁrst direct evidence showing the
structural-activity relationships of tea ﬂavonoids on inhibition of
TTR aggregation, it is most likely that multimodal activities of tea
polyphenols, with emphasis on their neurorescue/neuroregenerative
and mitochondrial stabilization actions, may potentiate their pro-
tective effects [36].
Pharmacokinetics and bioavailability of tea polyphenols in hu-
mans and rodents is poorly deﬁned [37]. However it is known that
gut absorption and metabolism of ﬂavonoids varies depending on
their chemical complexity. For instance, monomeric ﬂavan-3-ols are
principally absorbed in the small intestine while higher-molecular-
weight polymers require prior metabolism into phenolic acids by
the action of resident colonic microﬂora before absorption. Fol-
lowing absorption and passing through the circulatory system,
metabolites are excreted in urine in amounts equivalent to about
40% of total ﬂavonoid intake [38]. Taken this into account, different
strategies aiming ﬂavonoid bioavailability optimization have been
proposed [39], including EGCG encapsulation in chitosan particles
[40] or the design and semisynthesis O-acyl derivatives of EGCG
[41] or co-treatment with piperine [42].
Neverthless, compelling evidence from epidemiologic ob-
servations and experimental studies in mouse models have in-
dicated that green tea extracts (GTE) or EGCG consumption have
beneﬁcial effects in reducing the risk of neurodegeneration and
dementia [43–45].
We have shown previously [46] that sub-chronic supple-
mentation of FAP mice model with EGCG (100 mg/Kg/day) de-
creased TTR deposition along the gastrointestinal tract and per-
ipheral nervous system (PNS). These results have recently been
corroborated by an observational report on the effects of GTE
consumption in patients with TTR cardiomyopathy showing an
inhibitory effect of green tea and/or GTE on the progression of
cardiac amyloidosis [47].
In conclusion, the current work provides strong support for the
hypotheses that tea polyphenols, in particular galloyl esters, can
act as chemical chaperones that inhibit or redirect otherwise ag-
gregation-prone amyloidogenic intermediaries onto less ha-
zardous species [21]. On basis of the structure-activity studies
presented here, we identify the galloyl moiety as the key critical
structure feature for TTR chaperoning by ﬂavonoids. Our ﬁndings
provide new evidence for comprehensive understanding of the
mechanism of TTR toxicity inhibition by polyphenols and may
open perspectives for the design and development of innovative
disease-modifying drugs for the prevention and/or treatment of
TTR-related amyloidosis.Acknowledgments
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